# Study to Determine Optimal Dose and Evaluate Safety, Tolerability, and Pharmacokinetics of Progerinin in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS)

> **NCT06775041** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **PRG Science & Technology Co., Ltd.** · enrollment: 10 (actual)

## Conditions studied

- Hutchinson-Gilford Progeria Syndrome

## Interventions

- **DRUG:** Progerinin
- **DRUG:** Lonafarnib

## Key facts

- **NCT ID:** NCT06775041
- **Lead sponsor:** PRG Science & Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-13
- **Primary completion:** 2026-03
- **Final completion:** 2026-03
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06775041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06775041, "Study to Determine Optimal Dose and Evaluate Safety, Tolerability, and Pharmacokinetics of Progerinin in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS)". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT06775041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*